Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study)
Journal of the European Academy of Dermatology and Venereology,
Год журнала:
2024,
Номер
38(11), С. 2149 - 2155
Опубликована: Июль 17, 2024
Clinical
trials
and
real-life
data
have
reported
an
increased
incidence
of
conjunctivitis
in
patients
treated
with
dupilumab
for
their
atopic
dermatitis
(AD).
Although
mostly
mild
severity,
some
cases
will
appear
or
increase
after
initiation,
which
can
lead
to
discontinuation.
Язык: Английский
An Open-Label Prospective Observational Study of Tralokinumab in Atopic Dermatitis Patients with Inadequate Response to Dupilumab
Dermatitis,
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 1, 2024
Язык: Английский
The efficacy of dupilumab in patients affected by atopic dermatitis who previously failed tralokinumab
International Journal of Dermatology,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 11, 2024
Biologic
drugs
and
small
molecules
have
completely
changed
the
therapeutic
scenario
of
moderate-to-severe
forms
atopic
dermatitis
(AD).1
However,
there
are
still
patients
unresponsive
or
partially
responsive
to
these
new
approaches,
leading
need
for
data
evaluating
effectiveness
drug
switching.2
Among
biologics
currently
approved
AD
management,
dupilumab
is
a
human
monoclonal
antibody
immunoglobulin
G4
subclass,
which
acts
by
binding
interleukin
(IL)4
receptor
alpha
subunit,
shared
IL4
IL13
complexes,
thus
inhibiting
signaling
cascade
both
cytokines.
Tralokinumab
fully
IgG4
antibody,
specifically
binds
with
high
affinity,
thereby
its
interaction
receptors
neutralizing
biological
activity
this
cytokine.1
Although
regarding
switch
from
tralokinumab
has
been
consistent,3-5
concerning
opposite
treatment
change
scant.6
In
context,
our
study
aimed
investigate
after
failure.
monocentric,
retrospective
case
series,
15
(8
males,
53.33%,
mean
age
62.33
±
12.89
years,
duration:
25.20
26.24
years)
who
previously
failed
ineffectiveness
were
subsequently
treated
at
least
16
weeks
included.
The
following
scores
used
evaluate
severity:
Eczema
Area
Severity
Index
(EASI),
Pruritus–Numerical
Rating
Scale
(P-NRS),
Dermatology
Life
Quality
(DLQI).
Patient
features
severity
shown
in
Table
1.
At
beginning
treatment,
EASI,
DLQI,
P-NRS
24.80
4.86,
20.07
5.23,
7.53
1.68,
decreased
17.87
3.62,
12.07
3.43,
5.80
1.52
last
follow-up
(mean
26.13
5.53
weeks,
range
16–38),
respectively.
None
received
other
systemic
treatments
interruption
except
dupilumab.
All
subjects
showed
clinical
response
(last
follow-up:
EASI:
2.07
1.83;
DLQI:
1.20
1.26;
P-NRS;
1.07
1.10;
26.27
9.71
[range
16–52]).
Of
note,
all
weeks.
No
adverse
events
(AEs)
collected
during
either
tralokinumab.
Finally,
no
factors
such
as
age,
sex,
duration,
comorbidities,
duration
correlated
better
response.
To
date,
real-life
switching
Our
results
line
experience
recently
published
Tavoletti
et
al.
that
demonstrated
reduction
EASI
22.4
5.26
3
1.56
an
average
6.4
months
their
cohort
11
successfully
dupilumab,
without
AEs
reported.6
Moreover,
authors
reported
50%
within
1.7
1.29
(range
1–4)
according
(50%
1.93
1.03
1–4]).6
Globally,
suggest
importance
targeting
multiple
cytokines
involved
pathogenesis,
subset
could
be
unique
inhibition
IL13.
Indeed,
it
should
emphasized
may
inter-individual
variability
responses
versus
IL4/IL13
pathway.
Certainly,
inclusion
larger
more
diverse
patient
populations
allow
understanding
well
assessment
impact
patient-specific
(e.g.,
disease
duration)
determining
success
sum
up,
valuable
alternative
tralokinumab,
highlighting
further
studies
establish
guidelines
offer
tailored
approach.
manuscript
given
written
informed
consent
publication
details.
Data
supporting
findings
available
corresponding
author
upon
reasonable
request.
Язык: Английский
Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study
Alexandre Beyrouti,
Juliette Deuze,
Éric Fontas
и другие.
The Journal of Allergy and Clinical Immunology In Practice,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 1, 2024
Язык: Английский